Research shows that anti-fungal medicine may increase vulnerability to influenza and other viruses

November 21, 2013

Scientists at the University of Massachusetts Medical School (UMMS) and the Wellcome Trust Sanger Institute have discovered evidence that a widely used anti-fungal medicine increases susceptibility to flu infection in mice and cell cultures. Published online in Cell Reports, the study shows that Amphotericin B, commonly given to cancer and bone marrow transplant patients to fight invasive fungal infections, neutralizes an important anti-viral protein, making it easier for viruses to infect cells.

These findings suggest that taking the antifungal therapy may be functionally immunocompromised and vulnerable to influenza and potentially other viruses.

"While these studies don't confirm that such an interaction may translate into clinical relevance for patients, it does suggest that some vigilance is warranted, especially for patients who are undergoing treatment for cancer and may already have suppressed immune systems," said Abraham Brass, MD, PhD, assistant professor of microbiology & physiological systems and senior author of the study.

Paul Kellam, PhD, professor from the Wellcome Trust Sanger Institute and co-author of the study said, "This is an important discovery and the consequences for patients on certain anti-fungal treatments should now be investigated. Preventative flu vaccinations, rapid antiviral therapy or alternative anti-fungal treatment could be offered to these patients when at risk of flu infection."

Found in nearly all human cells, IFITM3 works to alter the cell membrane, making it more difficult for viruses, such as the influenza virus, to penetrate the cell's outer layer. When IFITM3 is inactive, influenza viruses can more readily infiltrate and infect the cell. Previous studies by Drs. Kellam and Brass and their colleagues have also shown that people who have a genetic variant in the IFITM3 gene are more susceptible to influenza.

Brass and his lab were working to understand how IFITM3 protects cells from viral infection when they discovered the link between Amphotericin B and influenza. "Several in the lab became contaminated with a fungus," said Brass. "We treated them with Amphotericin B, not knowing it would have an effect on IFITM3 activity. Surprisingly, when we tested for influenza infection we found no IFITM3 activity in the normal, wild type, cells. At that point, we began to suspect that Amphotericin B was having an effect on IFITM3."

This unexpected revelation opened up a new line of inquiry that revealed that Amphotericin B was preventing IFITM3 from fending off the influenza virus. "When we treated lung cancer cells with the anti-fungal drug, we saw the anti-viral protection normally provided by IFITM3 disappear," said Christopher R. Chin, research associate in the Brass lab and co-first author of the study.

To better appreciate the effects Amphotericin B has on IFITM3, Brass teamed up with Kellam to treat mice with the anti-fungal drug. The pair found that once the mice contracted influenza, they displayed the same, more severe flu symptoms as mice completely lacking the protective IFITM3 gene. In the absence of the virus, the mice treated with the Amphotericin B showed no signs of illness.

This research indicates that patients undergoing Amphotericin B anti-fungal treatments could potentially lose the protective effects of IFITM3, increasing the risk of infections in patients with already compromised immune systems.

"Sometimes a very useful drug can also have unforeseen effects," said Brass. "We now see that a major part of the body's natural defenses to is rendered inactive by Amphotericin B in cells and mice. It's our hope that reporting the consequences of this interaction may stimulate further translational studies and potentially guide patient care."

Both Kellam and Brass agree that further work is now needed to evaluate if this effect has any clinical significance for patients receiving Amphotericin B-based treatments.

Explore further: Genetics of flu susceptibility: Researchers find gene that can transform mild influenza to a life-threatening disease

More information: Cell Reports, Lin et al.: "Amphotericin B Increases Influenza A Virus Infection by Preventing IFITM3-mediated Restriction." dx.doi.org/10.1016/j.celrep.2013.10.033

Related Stories

Genetics of flu susceptibility: Researchers find gene that can transform mild influenza to a life-threatening disease

March 25, 2012
A genetic finding could help explain why influenza becomes a life-threating disease to some people while it has only mild effects in others. New research led by the Wellcome Trust Sanger Institute has identified for the first ...

New findings into conquering influenza

January 29, 2013
Reseachers from the University of Melbourne and The Walter and Eliza Hall Institute (WEHI) have discovered a new protein that protects against viral infections such as influenza.

Study reveals insight into how key protein protects against viral infections

April 2, 2012
Scientists from the University of Utah School of Medicine have discovered that a mouse protein called IFITM3 contributes to the body's defense against some types of viral infections by binding to an enzyme responsible for ...

Study reveals natural process that blocks viruses

April 17, 2013
The human body has the ability to ward off viruses by activating a naturally occurring protein at the cellular level, setting off a chain reaction that disrupts the levels of cholesterol required in cell membranes to enable ...

Fatty acids could lead to flu drug

March 7, 2013
Flu viruses are a major cause of death and sickness around the world, and antiviral drugs currently do not protect the most seriously ill patients. A study published March 7th by Cell Press in the journal Cell reveals that ...

Researchers suggest boosting body's natural flu killers

May 23, 2013
A known difficulty in fighting influenza (flu) is the ability of the flu viruses to mutate and thus evade various medications that were previously found to be effective. Researchers at the Hebrew University of Jerusalem have ...

Recommended for you

Scientists develop infection model for tickborne flaviviruses

August 22, 2017
National Institutes of Health (NIH) scientists have filled a research gap by developing a laboratory model to study ticks that transmit flaviviruses, such as Powassan virus. Powassan virus was implicated in the death of a ...

Zika virus stifles pregnant women's weakened immune system to harm baby, study finds

August 21, 2017
The Zika virus, linked to congenital birth defects and miscarriages, suppresses a pregnant woman's immune system, enabling the virus to spread and increasing the chances an unborn baby will be harmed, a Keck School of Medicine ...

Novel approach to track HIV infection

August 18, 2017
Northwestern Medicine scientists have developed a novel method of tracking HIV infection, allowing the behavior of individual virions—infectious particles—to be connected to infectivity.

Faulty gene linked to obesity in adults

August 18, 2017
Groundbreaking new research linking obesity and metabolic dysfunction to a problem in the energy generators in cells has been published by researchers from the Harry Perkins Institute of Medical Research and The University ...

Two lung diseases killed 3.6 million in 2015: study

August 17, 2017
The two most common chronic lung diseases claimed 3.6 million lives worldwide in 2015, according to a tally published Thursday in The Lancet Respiratory Medicine.

New test differentiates between Lyme disease, similar illness

August 16, 2017
Lyme disease is the most commonly reported vector-borne illness in the United States. But it can be confused with similar conditions, including Southern Tick-Associated Rash Illness. A team of researchers led by Colorado ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.